The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2023

Filed:

Jun. 15, 2017
Applicants:

Boehringer Ingelheim Animal Health Usa Inc., Duluth, GA (US);

Sanofi Pasteur, Duluth, GA (US);

Inventors:

Guillaume Rigaut, Lyons, FR;

Alexis Guy André Lucien Parisot, Lyons, FR;

Karelle De Luca, Villette De Vienne, FR;

Christine Michele Pierrette Andreoni, Villette D'Anthon, FR;

Lydie Remolue, Lyons, FR;

Marie Garinot, Lyons, FR;

Jean-François Cotte, Lozanne, FR;

Patricia Probeck-Quellec, Lyons, FR;

Jean Haensler, Grezieu la Varenne, FR;

Véronique Chambon, Curis-Au-Mont-D'Or, FR;

Philippe Talaga, Sainte Consorce, FR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); C08F 120/06 (2006.01); A61K 39/00 (2006.01); A61K 47/08 (2006.01); A61K 47/26 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 47/08 (2013.01); A61K 47/26 (2013.01); A61K 2039/555 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/57 (2013.01); A61K 2300/00 (2013.01); C08F 120/06 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.


Find Patent Forward Citations

Loading…